These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 36398521)
1. Synergistic effects of PI3K inhibition and pioglitazone against acute promyelocytic leukemia cells. Esmaeili S; Yousefi AM; Delshad M; Bashash D Mol Genet Genomic Med; 2023 Mar; 11(3):e2106. PubMed ID: 36398521 [TBL] [Abstract][Full Text] [Related]
2. Stimulation of Peroxisome Proliferator-Activated Receptor-Gamma (PPARγ) using Pioglitazone Decreases the Survival of Acute Promyelocytic Leukemia Cells through Up-Regulation of PTEN Expression. Esmaeili S; Safaroghli-Azar A; Pourbagheri-Sigaroodi A; Salari S; Gharehbaghian A; Hamidpour M; Bashash D Anticancer Agents Med Chem; 2021; 21(1):108-119. PubMed ID: 32807067 [TBL] [Abstract][Full Text] [Related]
3. Activation of PPARγ intensified the effects of arsenic trioxide in acute promyelocytic leukemia through the suppression of PI3K/Akt pathway: Proposing a novel anticancer effect for pioglitazone. Esmaeili S; Safaroghli-Azar A; Pourbagheri-Sigaroodi A; Salari S; Gharehbaghian A; Hamidpour M; Bashash D Int J Biochem Cell Biol; 2020 May; 122():105739. PubMed ID: 32169580 [TBL] [Abstract][Full Text] [Related]
4. Small molecule inhibitor of c-Myc 10058-F4 inhibits proliferation and induces apoptosis in acute leukemia cells, irrespective of PTEN status. Bashash D; Sayyadi M; Safaroghli-Azar A; Sheikh-Zeineddini N; Riyahi N; Momeny M Int J Biochem Cell Biol; 2019 Mar; 108():7-16. PubMed ID: 30639430 [TBL] [Abstract][Full Text] [Related]
5. Arsenic trioxide induces apoptosis and G2/M phase arrest by inducing Cbl to inhibit PI3K/Akt signaling and thereby regulate p53 activation. Li Y; Qu X; Qu J; Zhang Y; Liu J; Teng Y; Hu X; Hou K; Liu Y Cancer Lett; 2009 Nov; 284(2):208-15. PubMed ID: 19457607 [TBL] [Abstract][Full Text] [Related]
6. PI3K/mTOR dual-inhibition with VS-5584 enhances anti-leukemic efficacy of ponatinib in blasts and Ph-negative LSCs of chronic myeloid leukemia. Kayabasi C; Yelken BO; Asik A; Okcanoglu TB; Sogutlu F; Gasimli R; Susluer SY; Saydam G; Avci CB; Gunduz C Eur J Pharmacol; 2021 Nov; 910():174446. PubMed ID: 34461124 [TBL] [Abstract][Full Text] [Related]
7. Alteration of PPAR-GAMMA (PPARG; PPARγ) and PTEN gene expression in acute myeloid leukemia patients and the promising anticancer effects of PPARγ stimulation using pioglitazone on AML cells. Esmaeili S; Salari S; Kaveh V; Ghaffari SH; Bashash D Mol Genet Genomic Med; 2021 Nov; 9(11):e1818. PubMed ID: 34549887 [TBL] [Abstract][Full Text] [Related]
8. Inhibition of mitotic kinase Aurora suppresses Akt-1 activation and induces apoptotic cell death in all-trans retinoid acid-resistant acute promyelocytic leukemia cells. Xu DR; Huang S; Long ZJ; Chen JJ; Zou ZZ; Li J; Lin DJ; Liu Q J Transl Med; 2011 May; 9():74. PubMed ID: 21600017 [TBL] [Abstract][Full Text] [Related]
9. Neuroprotective and antioxidative effects of pioglitazone in brain tissue adjacent to the ischemic core are mediated by PI3K/Akt and Nrf2/ARE pathways. Zhao Y; Lützen U; Gohlke P; Jiang P; Herdegen T; Culman J J Mol Med (Berl); 2021 Aug; 99(8):1073-1083. PubMed ID: 33864097 [TBL] [Abstract][Full Text] [Related]
10. Autocrine IGF-1/IGF-1R signaling is responsible for constitutive PI3K/Akt activation in acute myeloid leukemia: therapeutic value of neutralizing anti-IGF-1R antibody. Chapuis N; Tamburini J; Cornillet-Lefebvre P; Gillot L; Bardet V; Willems L; Park S; Green AS; Ifrah N; Dreyfus F; Mayeux P; Lacombe C; Bouscary D Haematologica; 2010 Mar; 95(3):415-23. PubMed ID: 20007139 [TBL] [Abstract][Full Text] [Related]
11. Activation of integrin-linked kinase is a critical prosurvival pathway induced in leukemic cells by bone marrow-derived stromal cells. Tabe Y; Jin L; Tsutsumi-Ishii Y; Xu Y; McQueen T; Priebe W; Mills GB; Ohsaka A; Nagaoka I; Andreeff M; Konopleva M Cancer Res; 2007 Jan; 67(2):684-94. PubMed ID: 17234779 [TBL] [Abstract][Full Text] [Related]
12. Inhibition of PI3K Signaling Intensified the Antileukemic Effects of Pioglitazone: New Insight into the Application of PPARγ Stimulators in Acute Lymphoblastic Leukemia. Mokhtari Y; Yousefi AM; Bashash D Indian J Hematol Blood Transfus; 2023 Oct; 39(4):546-556. PubMed ID: 37786817 [TBL] [Abstract][Full Text] [Related]
13. Cell cycle-dependent activity of the novel dual PI3K-MTORC1/2 inhibitor NVP-BGT226 in acute leukemia. Kampa-Schittenhelm KM; Heinrich MC; Akmut F; Rasp KH; Illing B; Döhner H; Döhner K; Schittenhelm MM Mol Cancer; 2013 May; 12():46. PubMed ID: 23705826 [TBL] [Abstract][Full Text] [Related]
14. Synergistic effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway or NUP214-ABL1 fusion protein in human Acute Lymphoblastic Leukemia. Simioni C; Ultimo S; Martelli AM; Zauli G; Milani D; McCubrey JA; Capitani S; Neri LM Oncotarget; 2016 Nov; 7(48):79842-79853. PubMed ID: 27821800 [TBL] [Abstract][Full Text] [Related]
15. Combined BCL-2 and PI3K/AKT Pathway Inhibition in Holz C; Lange S; Sekora A; Knuebel G; Krohn S; Murua Escobar H; Junghanss C; Richter A Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674872 [TBL] [Abstract][Full Text] [Related]
16. Death-associated protein 5 (DAP5/p97/NAT1) contributes to retinoic acid-induced granulocytic differentiation and arsenic trioxide-induced apoptosis in acute promyelocytic leukemia. Ozpolat B; Akar U; Zorrilla-Calancha I; Vivas-Mejia P; Acevedo-Alvarez M; Lopez-Berestein G Apoptosis; 2008 Jul; 13(7):915-28. PubMed ID: 18491231 [TBL] [Abstract][Full Text] [Related]
17. PPARγ activation serves as therapeutic strategy against bladder cancer via inhibiting PI3K-Akt signaling pathway. Lv S; Wang W; Wang H; Zhu Y; Lei C BMC Cancer; 2019 Mar; 19(1):204. PubMed ID: 30845932 [TBL] [Abstract][Full Text] [Related]
18. Autophagy inhibition through PI3K/Akt increases apoptosis by sodium selenite in NB4 cells. Ren Y; Huang F; Liu Y; Yang Y; Jiang Q; Xu C BMB Rep; 2009 Sep; 42(9):599-604. PubMed ID: 19788862 [TBL] [Abstract][Full Text] [Related]
19. Combined Casein Kinase II inhibition and epigenetic modulation in acute B-lymphoblastic leukemia. Richter A; Roolf C; Hamed M; Gladbach YS; Sender S; Konkolefski C; Knübel G; Sekora A; Fuellen G; Vollmar B; Murua Escobar H; Junghanss C BMC Cancer; 2019 Mar; 19(1):202. PubMed ID: 30841886 [TBL] [Abstract][Full Text] [Related]
20. Binimetinib, a novel MEK1/2 inhibitor, exerts anti-leukemic effects under inactive status of PI3Kinase/Akt pathway. Sakakibara K; Tsujioka T; Kida JI; Kurozumi N; Nakahara T; Suemori SI; Kitanaka A; Arao Y; Tohyama K Int J Hematol; 2019 Aug; 110(2):213-227. PubMed ID: 31129802 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]